These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

928 related items for PubMed ID: 16105155

  • 1. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR, Gilbert RE, Yue DK.
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [Abstract] [Full Text] [Related]

  • 2. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
    Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C.
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
    [Abstract] [Full Text] [Related]

  • 3. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.
    Cochrane Database Syst Rev; 2020 Nov 09; 11(11):CD005613. PubMed ID: 33166419
    [Abstract] [Full Text] [Related]

  • 4. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.
    Diabetes Obes Metab; 2015 Jan 09; 17(1):15-22. PubMed ID: 24957785
    [Abstract] [Full Text] [Related]

  • 5. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
    Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB.
    Diabet Med; 2004 Nov 09; 21(11):1213-20. PubMed ID: 15498088
    [Abstract] [Full Text] [Related]

  • 6. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB.
    Diabetes Care; 2003 May 09; 26(5):1490-6. PubMed ID: 12716810
    [Abstract] [Full Text] [Related]

  • 7. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A, Schweitzer MA, Häring HU, 4001 Study Group.
    Ann Intern Med; 2003 Jun 17; 138(12):952-9. PubMed ID: 12809451
    [Abstract] [Full Text] [Related]

  • 8. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May 17; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 9. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes.
    Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A, European Insulin Glargine Study Group.
    Diabetes Metab Res Rev; 2005 May 17; 21(6):545-53. PubMed ID: 16021649
    [Abstract] [Full Text] [Related]

  • 10. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group.
    Diabetes Care; 2000 Aug 17; 23(8):1130-6. PubMed ID: 10937510
    [Abstract] [Full Text] [Related]

  • 11. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
    Warren E, Weatherley-Jones E, Chilcott J, Beverley C.
    Health Technol Assess; 2004 Nov 17; 8(45):iii, 1-57. PubMed ID: 15525480
    [Abstract] [Full Text] [Related]

  • 12. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.
    Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DB.
    Diabetes Care; 2003 Mar 17; 26(3):799-804. PubMed ID: 12610040
    [Abstract] [Full Text] [Related]

  • 13. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2021 Mar 04; 3(3):CD013498. PubMed ID: 33662147
    [Abstract] [Full Text] [Related]

  • 14. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin.
    Herwig J, Scholl-Schilling G, Böhles H.
    J Pediatr Endocrinol Metab; 2007 Apr 04; 20(4):517-25. PubMed ID: 17550216
    [Abstract] [Full Text] [Related]

  • 15. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.
    Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, Tulokas T, Hulme S, Hardy K, McNulty S, Hänninen J, Levänen H, Lahdenperä S, Lehtonen R, Ryysy L.
    Diabetologia; 2006 Mar 04; 49(3):442-51. PubMed ID: 16456680
    [Abstract] [Full Text] [Related]

  • 16. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
    Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators.
    Diabetes Care; 2003 Nov 04; 26(11):3080-6. PubMed ID: 14578243
    [Abstract] [Full Text] [Related]

  • 17. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU.
    Clin Ther; 2007 Aug 04; 29(8):1607-19. PubMed ID: 17919543
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.